Huseyin Sirma

Hamburg, HH 20246, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.

CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.

Journal: Cancer gene therapy

Published: September 21, 2020

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Journal: EMBO reports

Published: October 07, 2018

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Journal: EMBO reports

Published: March 09, 2016

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Journal: International journal of oncology

Published: November 25, 2014

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: January 08, 2014

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Journal: PloS one

Published: December 31, 2013

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 14, 2013

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Journal: The American journal of pathology

Published: June 17, 2013

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

Journal: Journal of clinical pathology

Published: April 06, 2013

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.

Journal: Molecular oncology

Published: March 25, 2013

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

Journal: Cancer research

Published: March 16, 2013

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.

Journal: The Prostate

Published: February 15, 2013

Showing 1-12 of 25

Last Updated: 09/26/2026